Acne Vulgaris (AV) - Competitive Landscape

Acne Vulgaris (AV) - Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in AV therapeutics.
  • GlobalData epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV.
  • Topical retinoids and topical antibiotics are usually the first-line therapy for mild-to-moderate acne.
  • The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline.
  • The US is emerging as the key country for conducting AV trials.
  • Acquisition was the most prevalent deal type in North America, Asia-Pacific, and Europe.
Scope

GlobalData’s AV: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the AV market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AV market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Report Scope
  • Abbreviations
  • Key Findings
  • Disease Overview
    • Disease Etiology
  • Epidemiology Overview
    • Epidemiology Overview - Diagnosed Prevalent Cases of AV in 2023 and 2026
  • Treatment Overview
    • Treatment Guidelines
    • Management Algorithm - Suggested Management Regimens
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in AV
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile - Paratek Pharmaceutical's Seysara
    • Marketed Drug Profile - Journey Medical's Amzeeq
    • Marketed Drug Profile - Bausch Health's Cabtreo
    • Marketed Drug Profile - InfectoPharm's Clienzo
    • Marketed Drug Profile - Sol-Gel Technologies/Galderma's Twyneo
    • Marketed Drug Profile - Maruho's Bepio
    • Marketed Drug Profile - Cosmo Pharmaceuticals' Winlevi
    • Marketed Drug Profile - Almirall/Chartwell Pharmaceutical's Acticlate
    • Marketed Drug Profile - GSK's Isotrex
    • Marketed Drug Profile - Ortho Dermatologics' Arazlo
    • Marketed Drug Profile - Galderma's Aklief
    • Marketed Drug Profile - Sun Pharmaceutical's Xyrosa/Tetradox
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Average Cost of Therapy for AV
    • Marketed Drugs - Time to Pricing and Reimbursement
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Late-Stage Pipeline Drugs in AV
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - PTSR and LoA in AV
    • Pipeline Drugs - PTSR and LoA in Dermatology and AV
  • Clinical Trials Assessment
    • Clinical Trials in AV - Historical Overview
    • Clinical Trials in AV - Overview by Phase
    • Clinical Trials in AV - Overview by Status
    • Clinical Trials in AV - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in AV - Trials with a Virtual Component
    • Clinical Trials in AV - Geographic Overview
    • Clinical Trials in AV - Single-Country and Multinational Trials by Region
    • Clinical Trials in AV - Top Sponsors with Breakdown by Phase
    • Clinical Trials in AV - Top Sponsors with Breakdown by Status
    • Clinical Trials in AV - Overview by Endpoint Status
    • Clinical Trials in AV - Overview by Race and Ethnicity
    • Clinical Trials in AV - Enrollment Data
    • Clinical Trials in AV - Overview of Sites by Geography
    • Clinical Trials in AV - Top 20 Countries for Trial Sites
    • Clinical Trials in AV - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for AV
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in AV by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in AV
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in AV
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in AV
  • Appendix
    • Methodology - Sales Forecasts
    • Methodology
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings